Research highlights the poor 5-year survival rates post-surgical resection for cholangiocarcinoma patients and the effectiveness of gemcitabine combined with platinum as first-line chemotherapy for advanced cases. Targeted therapy shows promise, but challenges include adverse reactions, drug resistance, and individual differences. The study emphasizes the need for further research to develop more effective and safe drugs, tailored treatment plans, and the use of precision oncology in cholangiocarcinoma management.
Review by Li Y, Yu J (…) Liu S et 3 al. in Ann Med